CounterX TherapeuticsCounterX TherapeuticsCounterX Therapeutics
  • Home
  • About
  • Platform
  • Pipeline
    • CTRX 101
    • Publications
  • News
  • Team
  • Contact

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.

Blog Categories

  • Media (2)
  • Press Release (4)
  • Publications (9)

Recent Posts

April 29, 2026

CounterX Therapeutics Invited to Present at Science2Startup

by pjwcreative
March 10, 2026

Puget Sound Business Journal: CounterX Therapeutics inks licensing deal for opioid abuse treatments

by Jacques Bouchy
March 9, 2026

CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose

by Jacques Bouchy
March 2, 2026

CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders

by Jacques Bouchy
December 3, 2025

Wired: A Fentanyl Vaccine Is About to Get its First Major Test

by Jacques Bouchy
October 29, 2025

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

by Jacques Bouchy

Recent Comments

No comments to show.

Tags

Media Press Release

April 29, 2026 in Press Release

CounterX Therapeutics Invited to Present at Science2Startup

pjwcreative 1 Like Post Comments Off on CounterX Therapeutics Invited to Present at Science2Startup

PRESS RELEASE CounterX Therapeutics Invited to Present at Science2Startup SEATTLE, WA – (April 29, 2026) CounterX Therapeutics today announced that the company has been selected to presen ...

Read More
  • Follow Us
  • Contact Us

©2026 CounterX Therapeutics. All Rights Reserved.